BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35778350)

  • 1. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
    Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
    Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
    Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
    Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
    Wang H; Nan S; Wang Y; Xu C
    J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
    Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
    Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired intratumoral natural killer cell function in head and neck carcinoma.
    Mele D; Pessino G; Trisolini G; Luchena A; Benazzo M; Morbini P; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
    Front Immunol; 2022; 13():997806. PubMed ID: 36341402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
    Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
    Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
    Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.
    Jacobs MT; Wong P; Zhou AY; Becker-Hapak M; Marin ND; Marsala L; Foster M; Foltz JA; Cubitt CC; Tran J; Russler-Germain DA; Neal C; Kersting-Schadek S; Chang L; Schappe T; Pence P; McClain E; Zevallos JP; Rich JT; Paniello RC; Jackson RS; Pipkorn P; Adkins DR; DeSelm CJ; Berrien-Elliott MM; Puram SV; Fehniger TA
    Clin Cancer Res; 2023 Oct; 29(20):4196-4208. PubMed ID: 37556118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
    Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
    Thangaraj JL; Phan MT; Kweon S; Kim J; Lee JM; Hwang I; Park J; Doh J; Lee SH; Vo MC; Chu TH; Song GY; Ahn SY; Jung SH; Kim HJ; Cho D; Lee JJ
    Cancer Immunol Immunother; 2022 Mar; 71(3):613-625. PubMed ID: 34282497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model.
    Yang J; Xiang J; Zhu M; Zhao Y; Zhou L; Hu B; Wang C
    Immunobiology; 2022 Jan; 227(1):152127. PubMed ID: 34968777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.
    Schilling B; Halstead ES; Schuler P; Harasymczuk M; Egan JE; Whiteside TL
    Cancer Immunol Immunother; 2012 Sep; 61(9):1395-405. PubMed ID: 22270713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
    Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
    Front Immunol; 2019; 10():879. PubMed ID: 31105701
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of irradiation-induced intercellular adhesion molecule-1 expression on natural killer cell-mediated cytotoxicity toward human cancer cells.
    Jeong JU; Uong TNT; Chung WK; Nam TK; Ahn SJ; Song JY; Kim SK; Shin DJ; Cho E; Kim KW; Cho D; Yoon MS
    Cytotherapy; 2018 May; 20(5):715-727. PubMed ID: 29572116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
    Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
    Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.